20,162 Shares in Genelux Co. (NASDAQ:GNLX) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Genelux Co. (NASDAQ:GNLX) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 20,162 shares of the company’s stock, valued at approximately $39,000.

A number of other institutional investors also recently modified their holdings of the company. Woodward Diversified Capital LLC grew its holdings in shares of Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock worth $6,983,000 after buying an additional 3,687 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Genelux by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock worth $6,578,000 after acquiring an additional 24,220 shares in the last quarter. Highbridge Capital Management LLC acquired a new stake in shares of Genelux in the second quarter valued at approximately $1,231,000. AMG National Trust Bank lifted its position in shares of Genelux by 49.7% in the second quarter. AMG National Trust Bank now owns 75,351 shares of the company’s stock worth $147,000 after purchasing an additional 25,000 shares in the last quarter. Finally, LifeSteps Financial Inc. boosted its holdings in Genelux by 50.2% during the second quarter. LifeSteps Financial Inc. now owns 66,536 shares of the company’s stock worth $130,000 after purchasing an additional 22,227 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.

Insider Transactions at Genelux

In related news, major shareholder Aladar Szalay sold 107,045 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $1.98, for a total value of $211,949.10. Following the sale, the insider now owns 925,228 shares in the company, valued at approximately $1,831,951.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 331,062 shares of company stock worth $736,831. 9.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GNLX. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Genelux in a research note on Thursday, August 15th. Roth Capital upgraded Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Genelux has an average rating of “Buy” and a consensus price target of $22.33.

Genelux Price Performance

Shares of GNLX stock opened at $2.37 on Tuesday. The company has a fifty day moving average price of $2.19 and a two-hundred day moving average price of $3.04. Genelux Co. has a one year low of $1.60 and a one year high of $26.07. The stock has a market cap of $81.41 million, a P/E ratio of -2.44 and a beta of -1.55.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities research analysts anticipate that Genelux Co. will post -0.9 EPS for the current fiscal year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.